




µCor™ Heart Failure and Arrhythmia Management System

ZOLL's µCor Heart Failure and Arrhythmia Management System is designed to help clinicians improve outcomes and reduce hospitalizations for heart failure patients with fluid management problems

Non-invasive Pulmonary Fluid Level Monitoring

- Novel radiofrequency technology to monitor pulmonary fluid levels, an early indicator for heart failure decompensation
- Continuous monitoring using the non-invasive, water resistant Sensor that can be worn by patients 24 hours a day
- Actionable clinical parameters recorded include Thoracic Fluid Index, heart rate, respiration rate, activity, posture and heart rhythm (ECG)



Alerting Physicians to Signs of Worsening Patient Condition

- Proprietary algorithms determine patient-specific trends in the data, allowing for early detection of deterioration in the patient's condition
- Certified technicians from ZOLL's Medicare-approved and Joint Commission-accredited Independent Diagnostic Testing Facility (IDTF) provide 24/7 monitoring and analysis of the patient's data, along with Weekly and End of Service reports
- Changes in a patient's trends per pre-defined criteria or physician's specifications prompt interim notifications to the health care provider
- Data in the notifications aid the physician in the diagnosis and identification of various clinical conditions, events and/or trends, allowing for timely intervention by a medical professional

µCor™ Heart Failure and Arrhythmia Management System

Heart Failure Readmissions on the Rise

- Every year in the US, more than 650,000 individuals are newly diagnosed with HF¹
- Heart failure is one of the largest clinical challenges facing healthcare today, affecting nearly 6 million Americans and accounting for 1.2 million hospitalizations every year²
- The current US expenditures for HF exceed \$30 billion annually, with 60–80 percent related to hospitalization³

ZOLL's µCor Heart Failure and Arrhythmia Management System is designed to help clinicians improve outcomes and reduce hospitalizations for heart failure patients with fluid management problems



Additional Information

For more information, contact ZOLL at **1-888-592-3798** or CardiacDiagnostics@zoll.com

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation. ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

¹Yancy CW et al. 2013 ACCF/AHA guideline for the management of heart failure, J Am Coll Cardiol. 2013;62:e147–239.

²Heidenreich PA et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association, Circ Heart Fail. 2013;6(3):606–619.

³Desai AS, Stevenson LW. Rehospitalization for heart failure: Predict or prevent? Circulation 2012;126(4):501-506.